🔗 Share this article

Given that the United States continues making sweeping adjustments to its vaccine recommendations, a particular individual has emerged somewhat surprisingly: Tracy Beth Høeg, a Danish American sports physician and public health researcher who rose to prominence by questioning coronavirus vaccines throughout the pandemic and has focused upon possible deaths following Covid vaccination in her short time at the Food and Drug Administration.

Planned Shifts to Pediatric Immunization Program

Public health authorities had intended to reveal sweeping changes to the childhood immunization program earlier this month, synchronizing the US with the Danish vaccine program, it is understood – a substantial departure that would put the US out of alignment with a large portion of the global community with little proof for benefit. The announcement has been pushed back until the coming year.

Rather than the top vaccines chief, Tracy Beth Høeg is listed to present at the gathering. She was just designated acting director of the FDA’s CDER, the fifth appointee to lead the division this year.

A Shift at the Regulatory Body

The acting appointment might represent a tighter collaboration between the pharmaceutical and vaccine centers as Dr. Høeg and Prasad consolidate power at the regulatory agency – and it suggests a greater focus upon rolling back previously authorized immunizations at the FDA.

Høeg has repeatedly called for halting some childhood vaccine recommendations in the US in order to be more similar to Denmark's approach, a society with nationalized medicine and a citizenry about the population of the state of Wisconsin.

In her initial comments, she has continued to focus on immunizations – traditionally the domain of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Doubts Over Background

Høeg has no apparent background in pharmaceutical research, regulation or leadership, which has been standard for previous leaders of the CBER. She has been employed at the FDA as a key advisor to the FDA chief and CBER since spring.

“She doesn’t seem to have the requisite experience” for running the CDER, said Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She is not versed in managing a sizeable institution. She lacks background in drug approvals.”

Former heads of CBER would “be deeply familiar with legal statutes and the science of drug development”, noted a former acting FDA commissioner. “Frankly, she doesn’t have the type of experience that previous people who headed the center have had.”

The drug center has an immense workload at the FDA, she pointed out.

“The public just zeroes in on the novel medication approvals, but the off-patent medication office approves a multitude of off-brand pharmaceuticals. There’s a biosimilars program, OTC medication office and more, and each of these have to be managed,” she explained. “The area you neglect, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a significant management element to the role, which supervises over 5,000 personnel. “It is a massive administrative position, if you do it right,” she concluded.

Agency Reaction and Disputed Programs

In response to inquiries about Høeg’s fitness for the role and whether this assignment indicates greater collaboration among agency officials on vaccines, a representative stated that the “inquiries are based on inaccurate premises”.

“Her experience matches the responsibilities of her role,” the spokesperson explained, noting the time Høeg spent counseling the agency head on “pharmaceutical safety and approval science, including predictive safety algorithms and shot safety tracking”.

As acting director, Høeg takes over the agency head's controversial expedited review system, a disputed one-day therapy clearance system that reportedly troubled her predecessors. “By what process are these therapies being chosen for this expedited pathway? Who is making the choices?” Dr. Howard questioned. “There’s a lot of confidentiality happening at the FDA right now.”

In general, he said, “the Food and Drug Administration appears to be shifting towards more relaxed regulations of most medications, except for vaccines.”

Public History on Immunizations

Concerning vaccines, Dr. Høeg has a more documented, if problematic, past, Howard have noted. She released a analysis using non-validated public submissions to assess the incidence of myocarditis after Covid vaccination. She advised the Florida surgeon general Joseph Ladapo, who allegedly have changed statistics to suggest Covid vaccines are pose a greater threat than they are.

Part of her “desired changes” for the new administration encompassed altering guidelines for novel immunizations and halting “unnecessary” immunizations, she stated post-election on a audio program. At the agency, Høeg has allegedly suggested barring teenage boys from receiving Covid vaccinations.

“She’s an all-around true believer who starts off with her beliefs and works backwards to retrofit the evidence in a highly deceptive, dishonest manner,” Dr. Howard argued.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with other contrarians, {like|